Precision BioSciences, Inc.

DTIL Healthcare Biotechnology

Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024. In the quarter to June 2026, revenue grew 37,272.4%, EPS grew 40.9%, free cash flow grew 33.7% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

5.77 0.40 −6.48%
Market cap
$170.3M
P/E
0.0×
Fwd P/E
−2.6×
Dividend yield
—
F-score
1/9
Altman Z
−4.31
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(132.91%) (69.52%) (61.52%) (205.16%)

+8 more TTM periods

Piotroski F-Score
— 2 1 1
ROA
(44.91%) (32.50%) (31.45%) (67.76%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(61.77%) (42.69%) (41.10%) (215.83%)
Average Days of Receivables
— 32.39 0.00 2.09
Free Cash Flow per Share
(2.02) (2.40) (5.18) (6.23)
Free Cash Flow
(52.32) (59.16) (66.48) (73.68)
Capital Expenditures
(0.42) (0.43) (0.63) (0.41)
Other line items
Cash ROIC
(33.70%) (29.62%) (28.87%) (87.84%)
Accounts Receivable Turnover
— 21.52 0.00 6.62
Accounts Payable Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
0.00 0.00 0.00 0.00
Tax Rate
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 119.13% 158.10% 7,967.77%
Selling, General and Administrative Expense of Revenue
0.00% 67.65% 94.09% 4,954.87%
Share Based Compensation of Revenue
0.00% 19.77% 29.73% 1,678.51%
Interest Coverage
(27.55) (28.36) (36.67) (61.05)
Operating CF/Net income
0.98 1.35 1.44 0.88
Depreciation/Fixed assets
2.45 1.93 1.45 0.97
Capex/Depreciation
(0.18) (0.19) (0.31) (0.21)
Revenue per Share
0.00 1.83 2.67 0.06
Operating CF per Share
(2.01) (2.38) (5.13) (6.20)
Capex per Share
(0.02) (0.02) (0.05) (0.03)
Capex to Sales
0.00 0.01 0.02 0.58

Fold the line items

Columns are period end dates